- Home
- PRQR
as 12-24-2024 1:42pm EST
ProQR Therapeutics NV is a biopharmaceuticals company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.
| Founded: | 2012 | Country: | Netherlands |
| Employees: | N/A | City: | N/A |
| Market Cap: | 309.5M | IPO Year: | 2014 |
| Target Price: | $7.60 | AVG Volume (30 days): | 611.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.33 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.61 - $4.62 | Next Earning Date: | 11-07-2024 |
| Revenue: | $20,506,357 | Revenue Growth: | 306.68% |
| Revenue Growth (this year): | 235.11% | Revenue Growth (next year): | -9.06% |
Latest ProQR Therapeutics N.V. News
PRQR Breaking Stock News: Dive into PRQR Ticker-Specific Updates for Smart Investing
Simply Wall St.
4 days ago
Is There An Opportunity With ProQR Therapeutics N.V.'s (NASDAQ:PRQR) 37% Undervaluation?
TipRanks
12 days ago
ProQR Therapeutics announces $8.1M in new funding from RSRT
GlobeNewswire
13 days ago
ProQR Therapeutics Announces $8.1 Million in New Funding from Rett Syndrome Research Trust to Expand RNA Editing Collaboration
GlobeNewswire
14 days ago
ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist
TipRanks
18 days ago
ProQR Therapeutics price target raised to $8 from $5 at JMP Securities
GlobeNewswire
19 days ago
ProQR Therapeutics to Host Virtual Analyst and Investor Event on December 11, 2024
Simply Wall St.
a month ago
ProQR Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
TipRanks
2 months ago
ProQR Therapeutics sees cash runway into mid-2027
Compare PRQR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PRQR ProQR Therapeutics N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.